Kurs
-0,69%
Kalender
| Est. tid* | ||
| 2026-10-27 | N/A | Kvartalsrapport 2026-Q3 |
| 2026-07-27 | N/A | Kvartalsrapport 2026-Q2 |
| 2026-05-08 | N/A | Kvartalsrapport 2026-Q1 |
| 2026-03-09 | N/A | Bokslutskommuniké 2025 |
| 2025-10-30 | N/A | Kvartalsrapport 2025-Q3 |
| 2025-07-31 | N/A | Kvartalsrapport 2025-Q2 |
| 2025-05-27 | - | Årsstämma |
| 2025-05-08 | - | Kvartalsrapport 2025-Q1 |
| 2025-02-27 | - | Bokslutskommuniké 2024 |
| 2024-10-31 | - | Kvartalsrapport 2024-Q3 |
| 2024-07-25 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-09 | - | Kvartalsrapport 2024-Q1 |
| 2024-05-07 | - | Årsstämma |
| 2024-03-21 | - | Bokslutskommuniké 2023 |
| 2024-02-29 | - | Bokslutskommuniké 2023 |
| 2023-10-31 | - | Kvartalsrapport 2023-Q3 |
| 2023-07-27 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-04 | - | Kvartalsrapport 2023-Q1 |
| 2023-05-02 | - | Årsstämma |
| 2023-03-02 | - | Bokslutskommuniké 2022 |
| 2023-02-27 | - | Extra Bolagsstämma |
| 2022-10-27 | - | Kvartalsrapport 2022-Q3 |
| 2022-09-08 | - | Extra Bolagsstämma |
| 2022-07-28 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-10 | - | Årsstämma |
| 2022-05-05 | - | Kvartalsrapport 2022-Q1 |
| 2022-03-03 | - | Bokslutskommuniké 2021 |
| 2021-10-28 | - | Kvartalsrapport 2021-Q3 |
| 2021-07-29 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-14 | - | Kvartalsrapport 2021-Q1 |
| 2021-03-31 | - | Bokslutskommuniké 2020 |
| 2020-10-22 | - | Kvartalsrapport 2020-Q3 |
| 2020-07-30 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-14 | - | Kvartalsrapport 2020-Q1 |
| 2020-05-12 | - | Årsstämma |
| 2019-11-25 | - | Extra Bolagsstämma |
February 25, 2025
Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the TD Cowen 45th Annual Healthcare Conference on Monday, March 3, 2025 at 11:50 a.m. ET.
A live webcast of the presentation may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately 30 days following the presentation.
About argenx
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker, globally in the U.S., Japan, Israel, the EU, the UK, China and Canada. The Company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn, X/Twitter, Instagram, Facebook, and YouTube.
Media:
Ben Petok
bpetok@argenx.com
Investors:
Alexandra Roy (US)
aroy@argenx.com
Lynn Elton (EU)
lelton@argenx.com